Sirna to Release Q4, FY 2005 Financials on March 1
Sirna Therapeutics said this week that it will release its fourth-quarter and full-year 2005 financial results on March 1.
The company also said it will hold a conference call to discuss the results at 4:30 pm EST on March 1.
A live webcast of the call can be accessed on Sirna's corporate website.
Sigma-Aldrich to Offer Rubicon's Genome Amplification Kits
Sigma-Aldrich said last week that it has signed a licensing deal allowing it to offer Rubicon Genomics' GenomePlex Whole Genome Amplification kits to service providers.
Rubicon Genomics will retain all rights to the kits for molecular diagnostics, and will continue its existing service business, Sigma-Aldrich said.
Additional terms of the arrangement were not disclosed.
CombiMatrix Shares Climb 6.6 Percent on Strong Q4 Revenue Growth
CombiMatrix this week reported fourth-quarter revenues of $3.6 million versus $522,000 in the year-ago period.
Total receipts for the period included $2.3 million in previously deferred revenues recognized from CombiMatrix's completion of its R&D agreement with Toppan Printing.
R&D costs increased 25 percent to $1.7 million from $1.4 million in the year-ago period.
Net losses in the fourth quarter narrowed 57 percent to $1.8 million from $4.1 million, CombiMatrix said.
The unit had around $20.2 million in cash and short-term investments as of Dec.31.